Want to see HK:6821 full AI Analyst Report?
Top Page
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
(6821)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$131.00
â–˛(13.42% Upside)
Action:Downgraded
Date:08/22/26
The score is primarily driven by strong financial stability and solid (though normalized) profitability, supported by an upward technical trend. These positives are meaningfully offset by weak free-cash-flow conversion and a high P/E valuation with a modest dividend yield.
Positive Factors
Integrated CDMO platform
Serving customers from development through commercial manufacturing can deepen relationships and support repeat business. This integrated CDMO model also creates opportunities to retain projects as drugs advance toward approval and ongoing supply.
Negative Factors
Weak free-cash-flow conversion
Limited conversion of accounting profit into free cash flow can constrain internally funded expansion and reduce financial flexibility. Negative recent free-cash-flow growth also suggests that working capital or investment requirements are absorbing a large share of operating cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated CDMO platform
Serving customers from development through commercial manufacturing can deepen relationships and support repeat business. This integrated CDMO model also creates opportunities to retain projects as drugs advance toward approval and ongoing supply.
Read all positive factors
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$74.17B
Dividend Yield1.25%
Average Volume (3M)640.69K
Price to Earnings (P/E)54.1
Beta (1Y)1.26
Revenue Growth18.78%
EPS Growth12.65%
CountryHK
Employees10,617
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.08
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$132.74Price Target Upside14.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.5
Revenue Forecast (FY)HK$9.38B
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, developm...
How the Company Makes Money
Asymchem Laboratories (Tianjin) Co., Ltd. makes money by charging pharmaceutical and biotech customers for outsourced chemistry development and manufacturing services. Key revenue streams typically include: (1) Process development and CMC services...
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.90B | 6.67B | 5.80B | 7.83B | 10.26B | 4.64B |
| Gross Profit | 2.87B | 2.80B | 2.46B | 4.00B | 4.86B | 2.06B |
| EBITDA | 1.27B | 1.85B | 1.58B | 3.03B | 4.08B | 1.41B |
| Net Income | 1.11B | 1.13B | 948.95M | 2.27B | 3.30B | 1.07B |
Balance Sheet | ||||||
| Total Assets | 20.70B | 20.28B | 19.29B | 19.77B | 18.24B | 15.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.78B | 7.44B | 7.33B | 9.02B | 7.44B | 6.64B |
| Total Debt | 238.99M | 256.47M | 282.53M | 118.71M | 138.35M | 434.49M |
| Total Liabilities | 2.74B | 2.63B | 2.43B | 2.26B | 2.54B | 2.55B |
| Stockholders Equity | 17.95B | 17.64B | 16.85B | 17.48B | 15.65B | 12.61B |
Cash Flow | ||||||
| Free Cash Flow | 120.37M | 137.22M | 124.33M | 2.31B | 1.14B | -1.55B |
| Operating Cash Flow | 1.50B | 1.41B | 1.25B | 3.55B | 3.29B | 113.15M |
| Investing Cash Flow | -1.42B | -633.20M | -1.18B | -2.69B | -4.67B | -2.21B |
| Financing Cash Flow | -345.47M | -344.83M | -1.93B | -542.03M | -742.53M | 6.21B |
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Technical Analysis
Positive
115.50
Price Trends
113.74
Positive
104.34
Positive
91.81
Positive
Market Momentum
2.98
Negative
50.67
Neutral
55.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6821, the sentiment is Positive. The current price of 115.5 is below the 20-day moving average (MA) of 118.77, above the 50-day MA of 113.74, and above the 200-day MA of 91.81, indicating a bullish trend. The MACD of 2.98 indicates Negative momentum. The RSI at 50.67 is Neutral, neither overbought nor oversold. The STOCH value of 55.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6821.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$205.76B | 36.75 | 10.64% | ― | 16.79% | 47.14% | |
69 Neutral | HK$74.17B | 54.05 | 6.34% | 1.29% | 18.78% | 12.65% | |
62 Neutral | HK$72.95B | -14.71 | -12.72% | ― | 53.48% | -120.02% | |
61 Neutral | HK$3.28B | 13.80 | 5.57% | ― | -12.90% | 33.65% | |
59 Neutral | HK$98.13B | 49.46 | 11.22% | 1.04% | 20.39% | 26.48% | |
58 Neutral | HK$2.55B | 49.86 | 1.98% | ― | 0.61% | 766.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
119.80
25.75
27.38%
HK:1548
Genscript Biotech
34.44
15.92
85.96%
HK:2269
Wuxi Biologics (Cayman)
51.00
18.08
54.92%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
33.20
11.76
54.87%
HK:1521
Frontage Holdings Corp.
1.29
-0.14
-9.79%
HK:1873
Viva Biotech Holdings
1.59
-0.89
-35.89%
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Corporate Events
Asymchem Laboratories Reports Strong Turnout and Regulated Voting at 2026 Extraordinary Meeting
Aug 20, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported the poll results of its third extraordinary general meeting of 2026, held on 20 August in Tianjin as an on-site meeting with parallel online voting for A shareholders via Shenzhen Stock Exchange s...
Asymchem Completes Small Share Repurchase Under 2025 Incentive Scheme
Aug 19, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has completed the repurchase and cancellation of 117,500 Restricted A Shares originally granted under its 2025 A Share restricted share incentive scheme to former employees who have resigned. Following the...
Asymchem Labs Sets Board Meeting to Approve 2026 Interim Results
Aug 12, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed Chinese pharmaceutical services group, operates through multiple subsidiaries to deliver laboratory-based support for drug development and related biotech activities across various mark...
Asymchem Calls 2026 EGM to Approve New Share Schemes and Biotech Investment
Jul 31, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a PRC-incorporated joint stock company with H shares listed in Hong Kong, operates in the pharmaceutical and biotechnology services sector, including activities through Shanghai Asymchem Biotechnology Dev...
Asymchem Plans 2026 H Share Restricted Scheme to Align Incentives
Jul 30, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has proposed the adoption of a new 2026 H Share Restricted Share Scheme to strengthen its long-term incentive framework for directors, senior management and employees. The plan, which involves issuing or a...
Asymchem Injects RMB1.24 Billion Into CDMO Subsidiary in Connected Deal
Jul 30, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a China-based CDMO services provider, is boosting the capital base of its non-wholly owned subsidiary Shanghai Asymchem Biotechnology Development. The move fits its broader strategy of using external inve...
Asymchem Laboratories Reports Strong Turnout at 2026 Extraordinary and Class Meetings
Jul 10, 2026
Asymchem Laboratories held its second extraordinary general meeting of 2026 alongside separate class meetings for its A shares and H shares in Tianjin on 10 July, with voting conducted both on site and online via Shenzhen Stock Exchange systems. T...
Asymchem Clarifies Size of H-Share Restricted Share Grant
Jul 8, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed Chinese pharmaceutical services company, is overseen by a board chaired by CEO Dr. Hao Hong and composed of executive, non-executive and independent non-executive directors. The company...
Asymchem Expands H Share Incentive Grants Without Diluting Shareholders
Jul 8, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has made a further grant of H share awards under its Restricted Share Scheme, allocating a total of 640,000 incentive H shares to executive directors and other employees. The grants, priced at RMB1.00 per ...
Asymchem Proposes 2026 A Share Incentive Scheme for Key Staff
Jul 8, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a PRC-based joint stock company listed in Hong Kong, operates in the pharmaceutical and biotechnology services industry with a focus on research, development and manufacturing support. Its operations rely...
Asymchem Aligns H Share Register Closure for Dividend and Shareholder Meetings
Jun 25, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has clarified administrative details around its final dividend for the year ended 31 December 2025 and shareholder meeting arrangements. The company is synchronizing the closure period of its H share regis...
Asymchem Calls 2026 EGM to Revise Share Incentives and Governance Policies
Jun 18, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has convened its second extraordinary general meeting of 2026 for 10 July in Tianjin, inviting eligible H shareholders on the Hong Kong register to attend and vote. The meeting will address a proposed repu...
Asymchem Sets July 2026 H Shareholders’ Meeting to Vote on Share Repurchase and Governance Changes
Jun 18, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has called its third H shares class meeting of 2026 to be held on July 10, 2026 in Tianjin, immediately after its second extraordinary general meeting and third A shares class meeting. The session will con...
Asymchem to Repurchase and Cancel Restricted A Shares After Staff Resignations
Jun 17, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has approved the repurchase and cancellation of 117,500 restricted A shares granted under its 2025 A Share restricted share incentive scheme, following the resignation of 15 non-connected incentive partici...
Asymchem adjusts articles to reflect share cancellation and registered capital cut
Jun 17, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has proposed amendments to its articles of association to reflect a reduction in registered capital following the repurchase and cancellation of part of the restricted A shares granted under its 2025 A sha...
Asymchem cancels 94,000 restricted A shares after staff departures
Jun 12, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has completed the repurchase and cancellation of 94,000 restricted A shares granted under its 2025 A Share restricted share incentive scheme, following the resignation of 13 incentive participants. As a re...
Asymchem Reports Voting Outcomes for 2025 AGM and 2026 Share Class Meetings
Jun 10, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported the poll results of its 2025 annual general meeting, along with the second class meetings for both its A shares and H shares for 2026, held on 10 June 2026 in Tianjin. The meetings were conducted ...
Asymchem Updates Final 2025 Dividend Terms and Withholding Tax for H-Shareholders
Jun 10, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has declared a final ordinary cash dividend of RMB 13 per 10 shares for the financial year ended 31 December 2025, with shareholder approval granted on 10 June 2026. For Hong Kong holders of H shares, the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.